Sophia Genetics reports Q2 EPS (33c), consensus (17c)

Reports Q2 revenue $18.32M, consensus $17.49M. “We delivered another strong quarter of revenue growth in Q2 with 16% year-over-year growth, as new business continues to ramp and transformative applications like MSK-ACCESS powered with SOPHiA DDMTM gain adoption,” said Jurgi Camblong, CEO and co-founder. “The scalable, hyper-efficient data processing capabilities of SOPHiA DDMTM enabled us to expand adjusted gross margins by 120bps year-over-year to 74.4%, despite the increase in volume and data computed. This, in combination with prudent cost management, brought cash burn to $8.7 million in the quarter, a 35% improvement year-over-year.”